Haystack MRD Test
Minimal Residual Disease Detection across multiple solid tumors
CommercialActive
Key Facts
Indication
Minimal Residual Disease Detection across multiple solid tumors
Phase
Commercial
Status
Active
Company
About Haystack MRD
Haystack MRD, founded in 2021 and based in San Francisco, is a commercial-stage diagnostics company specializing in highly accurate MRD detection. Its core technology, developed from foundational work by cancer genomics pioneers and further advanced by Quest Diagnostics, uses a proprietary, error-corrected sequencing method that checks both DNA strands to achieve a reported limit of detection of 0.0006%. The company leverages Quest Diagnostics' commercial scale and distribution to provide its test for applications in neoadjuvant response assessment, residual disease detection, treatment monitoring, and recurrence surveillance across multiple cancer types.
View full company profile